
Vaderis Raises $152M to Push HHT Drug Into Phase 3
Swiss biotech Vaderis Therapeutics closes an oversubscribed $152M Series B led by Goldman Sachs Life Sciences to fund a global Phase 3 trial of engasertib, a potential first-ever approved treatment for rare vascular disorder HHT.










